<DOC>
	<DOCNO>NCT02788045</DOCNO>
	<brief_summary>The purpose study assess safety/tolerability 2 different vaccine regimen prim trivalent Ad26.Mos.HIV boost trivalent Ad26.Mos.HIV Clade C gp140 plus adjuvant priming tetravalent Ad26.Mos4.HIV boost Ad26.Mos4.HIV Clade C glycoprotein ( gp ) 140 plus adjuvant . Immune response different vaccine schedule assess .</brief_summary>
	<brief_title>Safety , Tolerability Immunogenicity Study Different Vaccine Regimens Trivalent Ad26.Mos.HIV Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein ( gp ) 140 Healthy Human Immunodeficiency Virus ( HIV ) -Uninfected Adults</brief_title>
	<detailed_description />
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<mesh_term>Aluminum phosphate</mesh_term>
	<criteria>Are negative human immunodeficiency virus ( HIV ) infection screening Is healthy basis physical examination , medical history , electrocardiogram ( ECG ) , vital sign measurement perform screening Are willing/able adhere prohibition restriction specify protocol study procedure Female participant childbearing potential must negative serum pregnancy test ( beta human chorionic gonadotropin [ beta hCG ] ) Screening visit , negative urine pregnancy test predose Day 1 Are assess clinic staff low risk HIV infection Has chronic hepatitis B ( measure hepatitis B surface antigen test ) active hepatitis C ( measure hepatitis C virus [ HCV ] Ab test ; positive , HCV ribonucleic acid [ RNA ] PCR test use confirm active versus past HCV infection ) , active syphilis infection , chlamydia , gonorrhea , trichomonas . Active syphilis document serology unless positive serology due past treated infection Has thyroidectomy active thyroid disease require medication last 12 month ( exclude : stable thyroid supplementation ) Has major psychiatric illness and/or substance abuse problem past 12 month ( include hospitalization period work disability ) opinion investigator would preclude participation Has receipt license vaccine within 14 day prior first dose study vaccine/placebo , plan receive within 14 day first study vaccination , plan receive within 14 day second , third fourth vaccination Is recipient prophylactic therapeutic HIV vaccine candidate time , recipient experimental vaccine ( ) within last 12 month . For participant receive experimental vaccine ( except HIV vaccine ) 12 month ago , documentation identity experimental vaccine must provide sponsor , determine eligibility casebycase basis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>